Trials / Completed
CompletedNCT01019070
Hepatic Impaired Subjects Compared to Healthy Subjects Receiving Multi-dose BMS-650032
Multiple-Dose Pharmacokinetics of BMS-650032 in Subjects With Hepatic Impairment Compared to Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 28 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess the effects of hepatic impairment on the multiple dose pharmacokinetics of BMS-650032.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-650032 | Capsules, Oral, 200 mg, BID, 7 Days |
Timeline
- Start date
- 2009-12-01
- Primary completion
- 2011-08-01
- Completion
- 2011-08-01
- First posted
- 2009-11-25
- Last updated
- 2011-10-26
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01019070. Inclusion in this directory is not an endorsement.